Anagram Therapeutics Inc.
PrivateLast Round
Early Funding
May 7, 2026
Total Funding Raised
$251.8M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Anagram Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel, orally delivered enzyme therapeutics for the treatment of serious diseases caused by malabsorption syndromes and nutrient metabolism disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B2C
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Anagram Therapeutics Inc. Comparables
Compare Anagram Therapeutics Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nestlé | 74% | |
| AbbVie | 72% | |
| Chiesi Farmaceutici S.p.A. | 69% | |
Anagram Therapeutics Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | May 7, 2026 | ||||
| Grant | Apr 4, 2023 | ||||
| Grant | Sep 10, 2021 | ||||
| Grant | Feb 12, 2020 | ||||
| VC Round | Jun 29, 2017 |
Key People
Founding team and executive leadership
Anagram Therapeutics Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NIH RADx | Grant |
| Cystic Fibrosis Foundation | Early Funding, Grant |
| Blackstone Life Sciences | Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 22, 2026
Open roles increased to 4, 2.7x the trailing average.
- May 7, 2026
$250M raised, led by Blackstone Life Sciences.
Anagram Therapeutics Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Anagram Therapeutics Inc.'s valuation, stock price, and market status.